Skip to main content

Table 4 Safety of maintenance-Bevacizumab (total patients n = 35)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Toxicity

Grade 1

Grade 2

Grade 3

Grade 4

n(%)

n(%)

n(%)

n(%)

Bleeding

2 (5.7)

 

-

-

Protenuria

-

3 (8.5)

4 (11.4)

-

Hypertension

1 (2.8)

2 (5.7)

3 (8.5)

-

Neurotoxicity

1 (2.8)

-

-

-

LVS disfunction

1 (2.8)

-

-

-

Other events

  

Pneumonia 1 (2.8)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us